Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia. - Wikidata - awgldk - TriplyDB

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

http://www.wikidata.org/entity/Q33424543

about

Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.Idelalisib in the management of lymphoma.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.The Hidden Conundrum of Phosphoinositide Signaling in Cancer Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.Genomics of Immune Diseases and New Therapies.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib.A slowly developed severe cutaneous adverse reaction to idelalisib.

P2860

Q23923997-48207763-B795-43A6-9022-7ECB808DB6D2 Q33871417-86F746B9-D4C2-4690-ADBD-8657DBF05D65 Q34529311-1089A858-95B9-4CFB-8919-5639471BAC89 Q37079141-59F9B8DD-FBE1-40FE-A82B-054B069C20EA Q37391319-F3A7E24F-9782-4A68-A4F3-8B23E5DB4433 Q37587308-A83A159D-2F3E-4111-A459-42A65996E577 Q38560780-E136E4ED-A652-47BD-91AA-23244A9D6C90 Q39200835-CB9606D3-D669-41D9-8122-986582081707 Q41906865-E93CBC88-38C0-4C5C-9548-4504DA6973E8 Q49907839-57F19F7D-4C36-4D68-9510-8EBC91B732F4

P2860

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

http://www.wikidata.org/entity/Q33424543

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

@ast

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

@en

type

label

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

@ast

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

@en

prefLabel

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

@ast

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

@en

P1433

Q33424543-129AA73A-916B-4B17-A9CC-DDD97D4ABAAD

P1476

Q33424543-571D238B-AE5C-417C-BB40-E364E1B0977E

P2093

Q33424543-022E155B-E459-4D9A-856B-1AD9BC6A9D9E

Q33424543-AF2BC22B-3A20-4A30-B165-F42A21103323

P2860

Q33424543-144C7DE3-9508-48FB-AE85-C649EA8AB955

Q33424543-1AF7F7ED-6171-4CEF-9CD5-F26D63A4F13F

Q33424543-1C39C133-C7A2-4F71-B2E7-50DB9736D225

Q33424543-3C720566-2213-4128-9121-56A7C2D02713

Q33424543-4C47749E-5F72-42EE-AE52-405231E490DF

Q33424543-4D4E7B9F-ECE3-46DB-9488-B5ADD6770635

Q33424543-4F2181D6-3A50-45A4-9892-3C26BE790A21

Q33424543-5C433621-017C-4D5F-B820-8EBA975E3904

Q33424543-5DBF8C1E-222F-41A0-A99D-FE597A614345

Q33424543-78E2EAEC-9A33-40B7-8FF3-1E3477C61090

P304

Q33424543-6B17A796-5906-49FE-8A5B-7093DD339CFA

P31

Q33424543-817C13AA-B796-437C-81ED-192FD05CCD7B

P356

Q33424543-F7931DDA-FB29-40EE-9A31-C18E4957DD13

P407

Q33424543-EEB5B388-806A-477C-B5E7-C3AF8C9D9A8C

P433

Q33424543-30D7AFAF-A0B7-4A79-956D-0789F1AD69A3

P478

Q33424543-6420842C-211C-4DD5-A5C9-F6AA7A336732

P577

Q33424543-B37D569C-B447-4E70-AF5A-4FC9D1CA2C88

P698

Q33424543-21AC50CE-ECD3-4A2A-AC02-9DB4DA8B0A4B

P921

Q33424543-2BD6AEEF-C210-4227-A218-B1F4BFE0212E

Q33424543-A1FFCD30-2530-42FF-BDA9-2C53CCBDCD2C

P356

1060028015594813

P1433

Annals of Pharmacotherapy

P1476

Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.

@en

P2093

Abhishek Mangaonkar

http://www.w3.org/2001/XMLSchema#string

Arpita Shah

http://www.w3.org/2001/XMLSchema#string

P2860

New strategies in chronic lymphocytic leukemia: shifting treatment paradigms

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

How will B-cell-receptor-targeted therapies change future CLL therapy?

Chronic lymphocytic leukemia

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

P304

1162-1170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028015594813

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26185276

http://www.w3.org/2001/XMLSchema#string

P921